Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Hi, everybody. Good afternoon. I'm Ekaterina Knyazkova, from the pharma team here at JPMorgan. Pleased to be introducing Eagle. And from Eagle, we have the company's CEO, Scott Tarriff. And we'll have a Q&A session after the presentation. So if anybody has a question, feel free to submit that with the ask-a-question button, and I'll try to weave that into the Q&A.
And with that, I'll turn it over to Scott.
Thank you, Ekaterina. That was very kind of you. Thank you for everybody for joining us. It's a shame we are virtual and not in San Francisco, but hello to everyone.
Let me make some opening remarks before we turn it over to Q&A. But maybe I can start out with, and there's some slides here that people can look at. If you go to Slide 4, it's titled Eagle Pharmaceuticals financial position, portfolio and pipeline. That's a good place to start. If we look just at the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |